US5780587A
(en)
*
|
1990-08-24 |
1998-07-14 |
President And Fellows Of Harvard College |
Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
|
EP0971033B1
(en)
*
|
1991-01-21 |
2009-10-28 |
Elan Pharmaceuticals, Inc. |
Test and model for Alzheimer's disease
|
PT620849E
(en)
*
|
1992-01-07 |
2003-11-28 |
Elan Pharm Inc |
TRANSGENIC ANIMAL MODELS FOR ALZHEIMER'S DISEASE
|
US6610493B1
(en)
*
|
1993-06-17 |
2003-08-26 |
Brigham And Women's Hospital |
Screening compounds for the ability to alter the production of amyloid-β peptide
|
JPH09507746A
(en)
|
1993-10-27 |
1997-08-12 |
アテナ ニューロサイエンシズ,インコーポレイティド |
Transgenic animal containing APP allele with Swedish mutation
|
ATE278023T1
(en)
|
1994-01-27 |
2004-10-15 |
Univ Minnesota |
NON-HUMAN, TRANSGENIC MAMMALS WITH DEVELOPING NEUROLOGICAL DISEASE
|
US5877399A
(en)
*
|
1994-01-27 |
1999-03-02 |
Johns Hopkins University |
Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
|
US7427392B1
(en)
*
|
1994-11-14 |
2008-09-23 |
Elan Pharmaceuticals, Inc. |
Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
|
US5872101A
(en)
*
|
1995-01-06 |
1999-02-16 |
Sibia Neurosciences, Inc. |
Methods of treating neurodegenerative disorders using protease inhibitors
|
US5804560A
(en)
*
|
1995-01-06 |
1998-09-08 |
Sibia Neurosciences, Inc. |
Peptide and peptide analog protease inhibitors
|
US6717031B2
(en)
*
|
1995-06-07 |
2004-04-06 |
Kate Dora Games |
Method for selecting a transgenic mouse model of alzheimer's disease
|
CA2221986A1
(en)
*
|
1995-06-07 |
1996-12-19 |
Athena Neurosciences, Inc. |
Method for identifying alzheimer's disease therapeutics using transgenic animal models
|
US5894078A
(en)
*
|
1996-02-26 |
1999-04-13 |
Advanced Bioconcept, Inc. |
Transgenic mouse expressing C-100 app
|
US6071493A
(en)
*
|
1996-09-20 |
2000-06-06 |
Baylor College Of Medicine |
Method of screening for an agent that inhibits mononuclear phagocyte-plaque component complex formation
|
US6043283A
(en)
*
|
1996-09-20 |
2000-03-28 |
Baylor College Of Medicine |
Tyramine compounds and their neuronal effects
|
US5898094A
(en)
*
|
1996-10-21 |
1999-04-27 |
University Of South Florida |
Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes
|
US8173127B2
(en)
*
|
1997-04-09 |
2012-05-08 |
Intellect Neurosciences, Inc. |
Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
|
US6455757B1
(en)
|
1997-10-08 |
2002-09-24 |
The Regents Of The University Of California |
Transgenic mice expressing human APP and TGF-β demonstrate cerebrovascular amyloid deposits
|
US6175057B1
(en)
|
1997-10-08 |
2001-01-16 |
The Regents Of The University Of California |
Transgenic mouse model of alzheimer's disease and cerebral amyloid angiopathy
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
US6710226B1
(en)
|
1997-12-02 |
2004-03-23 |
Neuralab Limited |
Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
|
US7588766B1
(en)
|
2000-05-26 |
2009-09-15 |
Elan Pharma International Limited |
Treatment of amyloidogenic disease
|
US7179892B2
(en)
*
|
2000-12-06 |
2007-02-20 |
Neuralab Limited |
Humanized antibodies that recognize beta amyloid peptide
|
US6923964B1
(en)
|
1997-12-02 |
2005-08-02 |
Neuralab Limited |
Active immunization of AScr for prion disorders
|
US6761888B1
(en)
|
2000-05-26 |
2004-07-13 |
Neuralab Limited |
Passive immunization treatment of Alzheimer's disease
|
US6787523B1
(en)
|
1997-12-02 |
2004-09-07 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
US6905686B1
(en)
|
1997-12-02 |
2005-06-14 |
Neuralab Limited |
Active immunization for treatment of alzheimer's disease
|
US7790856B2
(en)
*
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
TWI239847B
(en)
*
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
US6913745B1
(en)
|
1997-12-02 |
2005-07-05 |
Neuralab Limited |
Passive immunization of Alzheimer's disease
|
US6750324B1
(en)
|
1997-12-02 |
2004-06-15 |
Neuralab Limited |
Humanized and chimeric N-terminal amyloid beta-antibodies
|
US20080050367A1
(en)
*
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
AU781126B2
(en)
*
|
1997-12-03 |
2005-05-05 |
Janssen Alzheimer Immunotherapy |
Method of suppressing beta-amyloid-related changes in Alzheimer's disease
|
US20050059802A1
(en)
*
|
1998-04-07 |
2005-03-17 |
Neuralab Ltd |
Prevention and treatment of amyloidogenic disease
|
CA2328591A1
(en)
*
|
1998-05-15 |
1999-11-25 |
Ortho-Mcneil Pharmaceutical, Inc. |
Irak modified transgenic animals
|
US20030147882A1
(en)
*
|
1998-05-21 |
2003-08-07 |
Alan Solomon |
Methods for amyloid removal using anti-amyloid antibodies
|
US6245884B1
(en)
|
1998-10-16 |
2001-06-12 |
Vivian Y. H. Hook |
Secretases related to alzheimer's dementia
|
US6313268B1
(en)
|
1998-10-16 |
2001-11-06 |
Vivian Y. H. Hook |
Secretases related to Alzheimer's dementia
|
US6737038B1
(en)
*
|
1998-11-12 |
2004-05-18 |
Bristol-Myers Squibb Company |
Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
|
CA2358086A1
(en)
*
|
1998-12-22 |
2000-06-29 |
Myriad Genetics, Inc. |
Protein-protein interactions in neurodegenerative disorders
|
US7115410B1
(en)
*
|
1999-02-10 |
2006-10-03 |
Elan Pharmaceuticals, Inc. |
β-secretase enzyme compositions and methods
|
AU4078900A
(en)
|
1999-04-06 |
2000-10-23 |
Harrington Arthritis Research Center |
Methods for tracking the progression of alzheimer's disease and identifying treatments using transgenic mice
|
US20030131364A1
(en)
*
|
1999-04-27 |
2003-07-10 |
Karen Duff |
Method for producing transgenic animal models with modulated phenotype and animals produced therefrom
|
WO2000071671A2
(en)
|
1999-05-26 |
2000-11-30 |
New York University |
New mutant genes in familial british dementia and familial danish dementia
|
US6787637B1
(en)
|
1999-05-28 |
2004-09-07 |
Neuralab Limited |
N-Terminal amyloid-β antibodies
|
UA81216C2
(en)
|
1999-06-01 |
2007-12-25 |
|
Prevention and treatment of amyloid disease
|
EP1265849B1
(en)
|
2000-03-23 |
2006-10-25 |
Elan Pharmaceuticals, Inc. |
Compounds and methods to treat alzheimer's disease
|
US6992081B2
(en)
|
2000-03-23 |
2006-01-31 |
Elan Pharmaceuticals, Inc. |
Compounds to treat Alzheimer's disease
|
AU2001245942A1
(en)
*
|
2000-03-24 |
2001-10-08 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Establishment of cellular manipulations which enhance oligo-mediated gene targeting
|
US7371920B2
(en)
*
|
2000-06-20 |
2008-05-13 |
The Governing Council Of The University Of Toronto |
Transgenic mouse model of neurodegenerative disorders
|
AU2001271686A1
(en)
|
2000-06-30 |
2002-01-14 |
Elan Pharmaceuticals, Inc. |
Compounds to treat alzheimer's disease
|
US6686449B2
(en)
|
2000-06-30 |
2004-02-03 |
Pharmacia & Upjohn Company |
Mutant presenilin 1 polypeptides
|
US6846813B2
(en)
|
2000-06-30 |
2005-01-25 |
Pharmacia & Upjohn Company |
Compounds to treat alzheimer's disease
|
US20030096864A1
(en)
*
|
2000-06-30 |
2003-05-22 |
Fang Lawrence Y. |
Compounds to treat alzheimer's disease
|
PE20020276A1
(en)
|
2000-06-30 |
2002-04-06 |
Elan Pharm Inc |
SUBSTITUTE AMINE COMPOUNDS AS ß-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER
|
EP1666452A2
(en)
|
2000-06-30 |
2006-06-07 |
Elan Pharmaceuticals, Inc. |
Compounds to treat Alzheimer's disease
|
EP2082749A3
(en)
|
2000-07-07 |
2010-06-30 |
Bioarctic Neuroscience AB |
Prevention and treatment of Alzheimer's disease
|
AU2007200047B2
(en)
*
|
2000-07-07 |
2009-11-26 |
Bioarctic Neuroscience Ab |
Prevention and treatment of Alzheimer's disease
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
TWI255272B
(en)
*
|
2000-12-06 |
2006-05-21 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
CA2438832A1
(en)
*
|
2001-02-23 |
2002-09-06 |
Elan Pharmaceuticals, Inc. |
Transgenic knockouts of bace-1
|
US6649196B2
(en)
|
2001-03-12 |
2003-11-18 |
Mayo Foundation For Medical Education And Research |
Methods of reducing β-amyloid polypeptides
|
US7081561B2
(en)
|
2001-03-16 |
2006-07-25 |
The Regents Of The University Of California |
Gene-targeted animal model of apolipoprotein E4 domain interaction and uses thereof
|
US7320790B2
(en)
*
|
2001-04-30 |
2008-01-22 |
Eli Lilly And Company |
Humanized antibodies
|
ATE396174T1
(en)
*
|
2001-06-01 |
2008-06-15 |
Elan Pharm Inc |
HYDROXYALKYLAMINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND THE USE THEREOF FOR THE TREATMENT OF ALZHEIMER'S DISEASE OR SIMILAR DISEASES
|
MXPA03011521A
(en)
|
2001-06-13 |
2004-03-18 |
Elan Pharm Inc |
Aminediols as agents for the treatment of alzheimer's disease.
|
US7199227B2
(en)
|
2001-06-14 |
2007-04-03 |
Bristol-Myers Squibb Company |
Polynucleotides encoding human histone deacetylase HDAC9c
|
MXPA04000140A
(en)
*
|
2001-06-27 |
2004-06-03 |
Elan Pharm Inc |
Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease.
|
EP1414491A4
(en)
*
|
2001-07-09 |
2005-07-06 |
Elan Pharm Inc |
Methods of inhibiting amyloid toxicity
|
US7829087B2
(en)
*
|
2001-07-09 |
2010-11-09 |
Elan Pharmaceuticals, Inc. |
Methods of treating cognitive impairment
|
WO2003006453A1
(en)
*
|
2001-07-10 |
2003-01-23 |
Elan Pharmaceuticals, Inc. |
Aminediols for the treatment of alzheimer's disease
|
MXPA04000338A
(en)
*
|
2001-07-10 |
2004-07-23 |
Upjohn Co |
Diaminediols for the treatment of alzheimer's disease.
|
US7297553B2
(en)
*
|
2002-05-28 |
2007-11-20 |
Nanosphere, Inc. |
Method for attachment of silylated molecules to glass surfaces
|
WO2003029169A2
(en)
*
|
2001-10-04 |
2003-04-10 |
Elan Pharmaceuticals, Inc. |
Hydroxypropylamines
|
US7176242B2
(en)
*
|
2001-11-08 |
2007-02-13 |
Elan Pharmaceuticals, Inc. |
N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives
|
AU2002352811A1
(en)
*
|
2001-11-19 |
2003-06-10 |
Elan Pharmaceuticals, Inc. |
Amino diols useful in the treatment of alzheimer's disease
|
MY139983A
(en)
*
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
AU2003303141A1
(en)
*
|
2002-04-30 |
2004-07-22 |
Elan Pharmaceuticals, Inc. |
Hydroxypropyl amides for the treatment of alzheimer's disease
|
US20040009602A1
(en)
*
|
2002-05-13 |
2004-01-15 |
The Government Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Services |
DNA modifying molecules and methods of use thereof
|
UY27967A1
(en)
*
|
2002-09-10 |
2004-05-31 |
Pfizer |
2-HINDROXI-1,3-DIAMINOALCANE OIL
|
US9535076B2
(en)
|
2002-09-12 |
2017-01-03 |
The Regents Of The University Of California |
Methods and compositions for eliciting an amyloid-selective immune response
|
BR0315157A
(en)
*
|
2002-10-09 |
2005-08-09 |
Rinat Neuroscience Corp |
Methods of treating alzheimer's disease by employing antibodies directed against amyloid beta peptide and compositions thereof
|
US9034337B2
(en)
|
2003-10-31 |
2015-05-19 |
Prothena Biosciences Limited |
Treatment and delay of outset of synucleinopathic and amyloidogenic disease
|
TW200509968A
(en)
*
|
2002-11-01 |
2005-03-16 |
Elan Pharm Inc |
Prevention and treatment of synucleinopathic disease
|
US8506959B2
(en)
|
2002-11-01 |
2013-08-13 |
Neotope Biosciences Limited |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
US20080014194A1
(en)
*
|
2003-10-31 |
2008-01-17 |
Elan Pharmaceuticals, Inc. |
Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
|
EP1563066A4
(en)
*
|
2002-11-04 |
2006-06-07 |
Bioarctic Neuroscience Ab |
Methods for the identification of agents that modulate the structure and processing of beta-amyloid precursor protein
|
AU2003287524A1
(en)
*
|
2002-11-04 |
2004-06-07 |
Icogenex Corporation |
Methods for the identification of agents that modulate the structure and processing of a membrane bound precursor protein
|
BR0316629A
(en)
*
|
2002-11-27 |
2005-10-11 |
Elan Pharm Inc |
Substituted urea and carbamates
|
AU2003303198A1
(en)
|
2002-12-19 |
2004-07-14 |
New York University |
Method for treating amyloid disease
|
DE10303974A1
(en)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid β (1-42) oligomers, process for their preparation and their use
|
UA87453C2
(en)
*
|
2003-02-01 |
2009-07-27 |
Вайет |
Use a fragment ав for treatment of alzheimer's disease
|
TW200512195A
(en)
|
2003-04-21 |
2005-04-01 |
Elan Pharm Inc |
Benzamide 2-hydroxy-3-diaminoalkanes
|
TW200505418A
(en)
*
|
2003-04-21 |
2005-02-16 |
Elan Pharm Inc |
Phenacyl 2-hydroxy-3-diaminoalkanes
|
WO2004110350A2
(en)
*
|
2003-05-14 |
2004-12-23 |
Torreypines Therapeutics, Inc. |
Compouds and uses thereof in modulating amyloid beta
|
US7358331B2
(en)
|
2003-05-19 |
2008-04-15 |
Elan Pharmaceuticals, Inc. |
Truncated fragments of alpha-synuclein in Lewy body disease
|
ES2632216T3
(en)
|
2003-05-19 |
2017-09-11 |
Prothena Biosciences Limited |
Truncated fragments of alpha-synuclein in Lewy body disease
|
TWI374893B
(en)
|
2003-05-30 |
2012-10-21 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
AT413336B
(en)
*
|
2003-09-12 |
2006-02-15 |
Mattner Frank Dr |
APHERESIS DEVICE
|
US7674599B2
(en)
|
2003-11-08 |
2010-03-09 |
Elan Pharmaceuticals, Inc. |
Methods of using antibodies to detect alpha-synuclein in fluid samples
|
CA2553973A1
(en)
*
|
2004-01-21 |
2005-08-04 |
Elan Pharmaceuticals, Inc. |
Methods of treatment of amyloidosis using aspartyl-protease inihibitors
|
US20060014737A1
(en)
*
|
2004-03-09 |
2006-01-19 |
Varghese John |
Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors
|
CA2556826A1
(en)
*
|
2004-03-09 |
2005-09-22 |
Elan Pharmaceuticals, Inc. |
Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
|
US20050239836A1
(en)
*
|
2004-03-09 |
2005-10-27 |
Varghese John |
Substituted hydroxyethylamine aspartyl protease inhibitors
|
JP2007528404A
(en)
*
|
2004-03-09 |
2007-10-11 |
エラン ファーマシューティカルズ,インコーポレイテッド |
Substituted ureas and carbamates, phenacyl-2-hydroxy-3-diaminoalkanes, and benzamido-2-hydroxy-3-diaminoalkane-based aspartic protease inhibitors
|
US20050239790A1
(en)
*
|
2004-03-09 |
2005-10-27 |
Varghese John |
Substituted hydroxyethylamine aspartyl protease inhibitors
|
SE0400707D0
(en)
|
2004-03-22 |
2004-03-22 |
Bioarctic Neuroscience Ab |
Transgenic animal model
|
WO2005110422A2
(en)
*
|
2004-05-19 |
2005-11-24 |
Boehringer Ingelheim International Gmbh |
Treatment of diseases associated with altered level of amyloid beta peptides
|
EP1761784B1
(en)
|
2004-05-24 |
2016-10-26 |
Universität Zu Köln |
Identification of ergothioneine transporter and therapeutic uses thereof
|
SE0401601D0
(en)
|
2004-06-21 |
2004-06-21 |
Bioarctic Neuroscience Ab |
Protofibril specific antibodies and uses thereof
|
EP1773758A1
(en)
*
|
2004-07-09 |
2007-04-18 |
Elan Pharmaceuticals, Inc. |
Oxime derivative hydroxyethylamine aspartyl-protease inhibitors
|
EP1773756A2
(en)
*
|
2004-07-09 |
2007-04-18 |
Elan Pharmaceuticals, Inc. |
Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
|
AP2007003890A0
(en)
*
|
2004-07-30 |
2007-02-28 |
Rinat Neuroscience Corp |
Antibodies directed against amy-loid-beta peptide and methods using same
|
US8383637B2
(en)
*
|
2004-08-06 |
2013-02-26 |
Jansssen Pharmaceutica N.V. |
2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
|
US8436006B2
(en)
*
|
2004-08-06 |
2013-05-07 |
Jansssen Pharmaceutica N.V. |
2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
|
US8426429B2
(en)
*
|
2004-08-06 |
2013-04-23 |
Jansssen Pharmaceutica N.V. |
2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
|
MX2007001679A
(en)
|
2004-08-09 |
2007-05-23 |
Elan Pharm Inc |
Prevention and treatment of synucleinopathic and amyloidogenic disease.
|
EP1802574A2
(en)
*
|
2004-08-27 |
2007-07-04 |
Elan Pharmaceuticals Inc. |
Methods of treatment of amyloidosis using ethanol cyclicamine derivatives aspartyl protease inhibitors
|
JP2008523815A
(en)
*
|
2004-12-15 |
2008-07-10 |
エラン ファーマ インターナショナル リミテッド |
Humanized amyloid beta antibody for use in improving cognition
|
JP2008524247A
(en)
*
|
2004-12-15 |
2008-07-10 |
エラン ファーマ インターナショナル リミテッド |
Amyloid beta antibody for use in cognitive improvement
|
ES2396555T3
(en)
*
|
2004-12-15 |
2013-02-22 |
Janssen Alzheimer Immunotherapy |
Antibodies that recognize beta amyloid peptide
|
DK2332408T3
(en)
|
2005-02-17 |
2013-12-02 |
Biogen Idec Inc |
Treatment of neurological diseases
|
MY148086A
(en)
|
2005-04-29 |
2013-02-28 |
Rinat Neuroscience Corp |
Antibodies directed against amyloid-beta peptide and methods using same
|
EP1746092A1
(en)
|
2005-07-22 |
2007-01-24 |
Exonhit Therapeutics SA |
Compounds and methods for treatment of amyloid-B-peptide related disorders
|
CA2617294A1
(en)
*
|
2005-08-03 |
2007-02-08 |
Boehringer Ingelheim International Gmbh |
Substituted ethane-1,2-diamines for the treatment of alzheimer's disease ii
|
US20100144681A1
(en)
*
|
2005-08-11 |
2010-06-10 |
Klaus Fuchs |
Compounds for the treatment of alzheimer's disease
|
CA2618474A1
(en)
*
|
2005-08-11 |
2007-02-15 |
Boehringer Ingelheim International Gmbh |
Compounds for treating alzheimer's disease
|
JP2009504612A
(en)
*
|
2005-08-11 |
2009-02-05 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Compounds for the treatment of Alzheimer's disease
|
EP1915339A1
(en)
*
|
2005-08-11 |
2008-04-30 |
Boehringer Ingelheim International GmbH |
Beta-secretase inhibitors for use in the treatment of alzheimer's disease
|
EP1937638A1
(en)
*
|
2005-10-12 |
2008-07-02 |
Elan Pharmaceuticals Inc. |
Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors
|
WO2007047305A1
(en)
*
|
2005-10-12 |
2007-04-26 |
Elan Pharmaceuticals, Inc. |
Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
|
CN102898519B
(en)
|
2005-11-30 |
2015-10-28 |
Abbvie公司 |
Monoclonal antibody of anti-amyloid beta protein and uses thereof
|
EP2289909B1
(en)
|
2005-11-30 |
2014-10-29 |
AbbVie Inc. |
Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies
|
ES2316209B1
(en)
*
|
2005-12-02 |
2009-11-13 |
Universidad Autonoma De Madrid |
ANZAL MODEL OF ALZHEIMER'S DISEASE, PROCEDURE OF OBTAINING AND ITS APPLICATIONS.
|
US7868022B2
(en)
*
|
2006-02-06 |
2011-01-11 |
Janssen Pharmaceutica Nv |
2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE)
|
US7932261B2
(en)
*
|
2006-02-06 |
2011-04-26 |
Janssen Pharmaceutica Nv |
Macrocycle derivatives useful as inhibitors of β-secretase (BACE)
|
US7776882B2
(en)
*
|
2006-02-06 |
2010-08-17 |
Baxter Ellen W |
2-amino-3,4-dihydro-quinoline derivatives useful as inhibitors of β-secretase (BACE)
|
RS51723B2
(en)
|
2006-03-23 |
2018-03-30 |
Bioarctic Neuroscience Ab |
Improved protofibril selective antibodies and the use thereof
|
US8784810B2
(en)
*
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
US20070292895A1
(en)
*
|
2006-05-19 |
2007-12-20 |
Xiao-Ping Shi |
Assays and methods to detect beta-secretase and its activity in body fluids and tissue extracts
|
WO2008042024A2
(en)
|
2006-06-01 |
2008-04-10 |
Elan Pharmaceuticals, Inc. |
Neuroactive fragments of app
|
CA2657681C
(en)
|
2006-07-14 |
2019-03-19 |
Ac Immune S.A. |
Humanized antibodies against beta amyloid protein
|
US8748656B2
(en)
|
2006-10-12 |
2014-06-10 |
Bhi Limited Partnership |
Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
PL2118300T3
(en)
*
|
2007-02-23 |
2015-11-30 |
Prothena Biosciences Ltd |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
US8147833B2
(en)
*
|
2007-02-23 |
2012-04-03 |
Neotope Biosciences Limited |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
PL3067066T3
(en)
|
2007-02-23 |
2019-09-30 |
Prothena Biosciences Limited |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
US8895004B2
(en)
|
2007-02-27 |
2014-11-25 |
AbbVie Deutschland GmbH & Co. KG |
Method for the treatment of amyloidoses
|
US20110286997A1
(en)
|
2007-03-13 |
2011-11-24 |
Hakon Hakonarson |
Genetic Alterations on Chromosome 16 and Methods of Use Thereof for the Diagnosis and Treatment of Type 1 Diabetes
|
AU2008242648B2
(en)
*
|
2007-04-18 |
2013-09-12 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of cerebral amyloid angiopathy
|
US8003097B2
(en)
*
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
US8613923B2
(en)
|
2007-06-12 |
2013-12-24 |
Ac Immune S.A. |
Monoclonal antibody
|
US8048420B2
(en)
|
2007-06-12 |
2011-11-01 |
Ac Immune S.A. |
Monoclonal antibody
|
EP2164834A2
(en)
|
2007-07-06 |
2010-03-24 |
Boehringer Ingelheim International GmbH |
Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture
|
CA2692604A1
(en)
*
|
2007-07-13 |
2009-01-22 |
Elan Pharmaceuticals, Inc. |
Compositions and methods for identifying substrate specificity of inhibitors of gamma secretase
|
JP5889529B2
(en)
|
2007-07-27 |
2016-03-22 |
ヤンセン・サイエンシズ・アイルランド・ユーシー |
Treatment of amyloidogenic diseases
|
EP2238166B1
(en)
|
2007-10-05 |
2013-11-27 |
Genentech, Inc. |
Use of anti-amyloid beta antibody in ocular diseases
|
JO3076B1
(en)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
Immunotherapy regimes dependent on apoe status
|
US20090163594A1
(en)
*
|
2007-10-31 |
2009-06-25 |
Elan Pharmaceuticals, Inc. |
Triple Assay System for Identifying Substrate Selectivity of Gamma Secretase Inhibitors
|
ES2400173T3
(en)
*
|
2008-01-28 |
2013-04-08 |
Janssen Pharmaceutica Nv |
6-Substituted thio-2-amino-quinoline derivatives useful as beta-secretase inhibitors (BACE)
|
CA2714008A1
(en)
*
|
2008-01-29 |
2009-08-06 |
Janssen Pharmaceutica N.V. |
2-amino quinoline derivatives useful as inhibitors of .beta.-secretase (bace)
|
DK2257643T3
(en)
|
2008-02-19 |
2015-06-29 |
Philadelphia Children Hospital |
Identification of pediatric onset of inflammatory bowel disease-loco and methods of use thereof for diagnosis and treatment thereof
|
AU2009246134B2
(en)
|
2008-05-16 |
2016-03-03 |
The Children's Hospital Of Philadelphia |
Genetic alterations on chromosomes 21q, 6q and 15q and methods of use thereof for the diagnosis and treatment of type I diabetes
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
US20110023152A1
(en)
*
|
2008-12-04 |
2011-01-27 |
Sigma-Aldrich Co. |
Genome editing of cognition related genes in animals
|
DK2448968T3
(en)
|
2009-06-29 |
2021-04-12 |
Bioarctic Ab |
ANTIBODIES SELECTIVE FOR N-TERMINAL-TRUNKED AMYLOID-ß PROTOFIBRILLS / OLIGOMERS
|
WO2011130377A2
(en)
|
2010-04-15 |
2011-10-20 |
Abbott Laboratories |
Amyloid-beta binding proteins
|
EP2598882B1
(en)
|
2010-07-30 |
2017-07-26 |
AC Immune S.A. |
Safe and functional humanized antibodies for use in treating an amyloidosis
|
CA2808187A1
(en)
|
2010-08-14 |
2012-02-23 |
Abbvie Inc. |
Amyloid-beta binding proteins
|
JP6250394B2
(en)
|
2010-08-19 |
2017-12-20 |
バック・インスティテュート・フォー・リサーチ・オン・エイジング |
Method for treating mild cognitive impairment (MCI) and related disorders
|
DK2827711T3
(en)
|
2012-03-19 |
2019-09-23 |
Buck Inst Res Aging |
APP-SPECIFIC BACE INHIBITORS (ASBIs) AND USE THEREOF
|
WO2014127042A1
(en)
|
2013-02-12 |
2014-08-21 |
Buck Institute For Research On Aging |
Hydantoins that modulate bace-mediated app processing
|
CN112390881A
(en)
|
2014-07-10 |
2021-02-23 |
生命北极神经科学公司 |
Improved a β protofibril binding antibodies
|
EP3212811B1
(en)
|
2014-10-29 |
2020-09-09 |
The Children's Hospital of Philadelphia |
Diagnosis of genetic alterations associated with eosinophilic esophagitis
|
CN108697659A
(en)
|
2015-08-21 |
2018-10-23 |
费城儿童医院 |
For treating and the composition being applied in combination and method of diagnosis of autoimmune disease
|
JP2018525447A
(en)
|
2015-08-27 |
2018-09-06 |
ナントネウロ,エルエルシー |
Compositions for APP selective BACE inhibition and uses therefor
|
KR102472011B1
(en)
|
2016-05-12 |
2022-11-28 |
버크 인스티튜트 포 리서치 온 에이징 |
Compounds that promote normal processing of APP
|